Mechanistic evaluation and validation of the neuroprotective effects CBD in an in vitro model of Parkinson’s Disease

Langara College is collaborating with Jazz Pharmaceuticals to develop an understanding of how cannabidiol (CBD) binds to targets and induces physiological changes in normal dopaminergic neurons compared to those modified to replicate Parkinson’s Disease (PD). We are submitting an NSERC CCI ARD proposal to obtain $120,000 for this project. The industrial partner has pledged to provide $30,000 in-cash and $60,000 in-kind contributions. This proposal outlines a one-year trial project that may expand into a larger program of research at the end of this term. The overarching research question relevant to Jazz is whether their existing drug, Epidiolex®, can be used to mitigate PD symptoms and/or disease progression. To support the expanded use of CBD, and in turn Epidiolex®, in improving outcomes for patients with PD, a greater understanding of the effect of cannabinoids on neuronal cell function and efficacy in diseased cells is needed. The Kalra lab and Jazz will work collaboratively to examine the effects of CBD alone or in combination with other clinically relevant, non-psychoactive cannabinoids (Cannabinol (CBN) and Cannabigerol (CBG)) in abrogating the cellular pathophysiology of neurological diseases starting with PD. The proposal described herein has three specific aims: i) to develop and characterize normal neuronal and

Faculty Supervisor:

Jessica Kalra

Student:

Partner:

Jazz Pharmaceuticals

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Langara College

Program: